Immunotherapy Boosts Chemotherapy in Combating Stage 3 Colon Cancer | OncLive Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone. @mayocliniccancer.bsky.social #crcsm #oncology
www.onclive.com/view/immunot...

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma | JCO Oncology Practice PURPOSEStandard adjuvant treatment for stage III colorectal cancer (CRC) combines intravenous oxaliplatin with a fluoropyrimidine, either with intravenous 5-fluorouracil with folinic acid…

CapeOx vs FOLFOX for adjuvant treatment in people w stage III colorectal #cancer & a diverting stoma:

- ⬆️ hospitalizations, mostly GI effects (35% vs 18%)
- ⬆️ rate of dose-reducing oxali (92% vs 40%)
- ⬆️ diarrhea, mucositis, HFS

😨 mFOLFOX6 much better for QOL. #CRCSM ascopubs.org/doi/10.1200/...

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRmdkC
@ASCO

#SocialListening #LucidQuest

Landmark Alliance ATOMIC trial establishes new standard of care for patients with dMMR #coloncancer. Learn more, visit https://bit.ly/ATOMIC2026 #ATOMIC #NCI #NCTN #CancerResearch #Alliance-A021502 #CRCsm

Analysis of 79,090 patients shows early-onset #colorectalcancer treatment delays are more common in all-urban areas. Delays exceeding 90 days disproportionately affect young male and minority groups. From @jamanetworkopen.com.

https://bit.ly/4rREKfT

#crcsm #CCAM #ColorectalCancerAwarnessMonth

As we observe #ColorectalCancerAwarenessMonth, new research examines how community physicians navigate third-line treatment for metastatic disease.

Read more here: https://bit.ly/40w377q

#CCAM #crcsm #mCRC

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRcFzr
@ASCO

#SocialListening #LucidQuest

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRQxmX
@ASCO

#SocialListening #LucidQuest

#ColorectalCancerAwarenessMonth: Nurse-led interventions significantly increase screening adherence (OR=2.51-6.14). Specialized care improves bowel prep and patient quality of life. 🩺

From @cancercaremascc.bsky.social.

Read the review: https://bit.ly/4aPjoKS

#crcsm #CRCAM

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRF805
@ASCO

#SocialListening #LucidQuest

BREAKING 🚨: @fda.gov Grants Full Approval to Encorafenib Plus Cetuximab/Chemotherapy for BRAF V600E+ mCRC

Check out the article below to learn more about this regulatory decision! 👇 #crcsm #oncology #FDAapproved

onclive.com/view/fda-gra...

James Van Der Beek’s Struggles With Colorectal Cancer Mirrored Those of Many Americans Van Der Beek was diagnosed with stage III colorectal cancer after noticing a change in his bowel movements and undergoing a colonoscopy.

The passing of #JamesVanDerBeek at age 48 underscores the rising clinical challenge of early-onset #colorectalcancer.

• CRC in adults <55 increased from 11% to 20%
• Estimated monthly costs for advanced care: ~$11,000

Read the review: https://bit.ly/4aC1fyy

#Oncology #PublicHealth #crcsm

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TR4sCY
@ASCO

#SocialListening #LucidQuest

New Colorectal Cancer Clinic at MD Anderson The University of Texas MD Anderson Cancer Center is opening a new colorectal center next week, expanding space for patients with colon, rectal and anal cancers.

I have dreamed of an early-onset colorectal cancer center at @mdanderson.bsky.social for years & it’s finally here!

TY Dr.Nancy You & Dr. Van Morris & so many others that made this happen! More space to save more lives!

Read more: bit.ly/4aqHwmR

#crcsm #ayacsm #cancer #colorectalcancer

LGB patients face significant #colorectalCancer knowledge gaps and barriers to care. 🩺

• 1 in 6 LGBTQ+ adults avoid care due to discrimination.
• Early detection: 91% survival vs. 14% late-stage.

Read the review: https://bit.ly/4aIyZKR

#CRCsm #LGBThealth #Oncology

Encorafenib/Cetuximab Plus FOLFIRI Prolongs PFS Over SOC in BRAF V600E–Mutant mCRC | OncLive Topline data from cohort 3 of BREAKWATER showed improvements in key secondary end points of PFS and OS in previously treated, BRAF V600E–mutant mCRC.

Encorafenib/Cetuximab Plus FOLFIRI Prolongs PFS Over SOC in BRAF V600E–Mutant mCRC
#crcsm #oncology
www.onclive.com/view/encoraf...

‘How I knew I had colorectal cancer’: Six survivors share their symptoms What are the symptoms of colorectal cancer, and when should you see a doctor? Gastroenterologist David Richards, M.D., weighs in on when to see a doctor, and six survivors share how they knew they had...

“How I knew I had colorectal cancer”
🦋Six survivors share their symptoms
#ColorectalCancer #ColonCancer #RectalCancer
#ColorectalCancerAwareness #ColonCancerAwareness
#GetScreened
#BlueForCRC
#DressInBlueDay
#CRCsm
#LynchSyndrome #Medsky #fuckcancer #Bluesky #ChronicIllness #art #oc #digitalart

ASCO GI 2025 SoMe Report.pdf

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQvxV7
@ASCO

#SocialListening #LucidQuest

Catherine O'Hara's Death Puts Spotlight on Rectal Cancer Emmy winner's diagnosis could normalize a disease many patients struggle to talk about

💔 a PE?!?
#CRCSM
#oncosky
#cancersky

Elevated B12 Is a Potential Biomarker for Worse Survival in Colon Cancer In this global network study, researchers examined vitamin B12 levels as a possible biomarker for outcomes in colon cancer.

Researchers have identified an elevated vitamin B12 level as a potential biomarker for outcomes in patients with #coloncancer. Published in @aacrjournals.bsky.social.

https://bit.ly/45Up4R1

#crcsm

Effects of a structured exercise program on motivational outcomes in patients with Colon cancer AbstractBackground. CHALLENGE was the first phase 3 trial to examine the effects of exercise on cancer-related survival and, therefore, required a substant

Our team report the SEP intervention in the #CHALLENGETrial successfully targeted the social cognitive beliefs associated with sustained moderate-vigorous #PhysicalActivity #CRCSM #SuppOnc #SurvOnc
@cctg.bsky.social @gicancertrials.bsky.social @cancerresearchuk.org
doi.org/10.1093/jnci...

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQkJJF
@ASCO

#SocialListening #LucidQuest

GLP-1 Use Lowers Colorectal Cancer Risk by a Third Compared to Aspirin Use - Oncology Nurse Advisor In this study, researchers matched patients using GLP-1RA therapy to those using aspirin to compare colorectal cancer incidence in each population.

The incidence of #colorectalcancer among users of GLP-1RAs was approximately 36% lower than that observed among aspirin users. Presented at @ascocancer.bsky.social #GI26, covered by @cancertherapyadv.bsky.social.

https://bit.ly/3Z7ToUj

#GLP1 #crcsm

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQYRN4
@ASCO

#SocialListening #LucidQuest

GLP-1 Use Lowers Colorectal Cancer Risk by a Third Compared to Aspirin Use The use of GLP-1 receptor antagonist therapy has led to a greater reduction in colorectal cancer incidence than has been observed with aspirin.

The use of GLP-1 receptor antagonist therapy has led to a greater reduction in #colorectalcancer incidence than has been observed with aspirin. Presented at #GI26.

https://bit.ly/45jGd6a

#crcsm #GLP1RA

Alors que janvier s’achève, nous soulignons le mois de sensibilisation au cancer chez les pompiers et les remercions pour leur travail. Selon CIRC, les pompiers canadiens courent un risque accru de 19 % de développer un cancer colorectal. 💙 #crcsm

As January ends, we recognize #FirefighterCancerAwarenessMonth and thank firefighters for their service. According to the International Agency for Research on Cancer (IARC), firefighters in Canada face a 19% higher risk of colorectal cancer. 💙
#crcsm

Poor Neighborhoods Linked to Early-Onset CRC Mortality Investigators assessed the association between race, ethnicity and neighborhood-level SES with mortality among young adults with mCRC.

Living in neighborhoods with lower #socioeconomic status is linked to an increased risk of death among young adults with metastatic #colorectalcancer. Published in @jamaoncology.com.

https://bit.ly/49Srock

#mCRC #crcsm

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQPfK2
@ASCO

#SocialListening #LucidQuest

Encorafenib/Cetuximab Plus FOLFIRI Represents Potential New Frontline SOC in BRAF V600E+ mCRC | OncLive Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Encorafenib/Cetuximab Plus FOLFIRI Represents Potential New Frontline SOC in BRAF V600E+ mCRC @skopetz.bsky.social @mdanderson.bsky.social @ascocancer.bsky.social #GI26 #oncology #crcsm www.onclive.com/view/encoraf...